NZ717866A - Compositions and methods for treating bacterial infections using ceftaroline - Google Patents
Compositions and methods for treating bacterial infections using ceftarolineInfo
- Publication number
- NZ717866A NZ717866A NZ717866A NZ71786610A NZ717866A NZ 717866 A NZ717866 A NZ 717866A NZ 717866 A NZ717866 A NZ 717866A NZ 71786610 A NZ71786610 A NZ 71786610A NZ 717866 A NZ717866 A NZ 717866A
- Authority
- NZ
- New Zealand
- Prior art keywords
- ceftaroline
- compositions
- methods
- bacterial infections
- treating bacterial
- Prior art date
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided is the use of ceftaroline fosamil in the treatment of a complicated skin and skin structure infection or community-acquired bacterial pneumonia, in a patient having impaired renal function with creatinine clearance of less than 50ml/min, wherein said treatment comprises providing a dosage form comprising about 300 mg of ceftaroline fosamil and L-arginine and adding about 20 ml of sterile water to the dosage form to form a constituted solution that has a pH of about 4.8 to about 6.5 and administration of the constituted solution to the patient intravenously every 12 hours by infusion over one hour.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24412009P | 2009-09-21 | 2009-09-21 | |
| US29490110P | 2010-01-14 | 2010-01-14 | |
| PCT/US2010/049659 WO2011035305A1 (en) | 2009-09-21 | 2010-09-21 | Compositions and methods for treating bacterial infections using ceftaroline |
| NZ702479A NZ702479A (en) | 2009-09-21 | 2010-09-21 | Compositions and methods for treating bacterial infections using ceftaroline |
| NZ59893510 | 2010-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ717866A true NZ717866A (en) | 2017-09-29 |
Family
ID=56132537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ702479A NZ702479A (en) | 2009-09-21 | 2010-09-21 | Compositions and methods for treating bacterial infections using ceftaroline |
| NZ717866A NZ717866A (en) | 2009-09-21 | 2010-09-21 | Compositions and methods for treating bacterial infections using ceftaroline |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ702479A NZ702479A (en) | 2009-09-21 | 2010-09-21 | Compositions and methods for treating bacterial infections using ceftaroline |
Country Status (1)
| Country | Link |
|---|---|
| NZ (2) | NZ702479A (en) |
-
2010
- 2010-09-21 NZ NZ702479A patent/NZ702479A/en unknown
- 2010-09-21 NZ NZ717866A patent/NZ717866A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ702479A (en) | 2016-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013028813A2 (en) | 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | |
| BR112015008804A2 (en) | mastitis treatment and prevention | |
| BR112013032974A2 (en) | "1,6-diazabicyclo [3,2,1] -octan-7-one derivatives, their uses, and pharmaceutical compositions". | |
| NZ612105A (en) | Human milk oligosaccharides for modulating inflammation | |
| SG10201405826RA (en) | Inhibitors of influenza viruses replication | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| MX2011009709A (en) | Compounds for treating inflammation and pain. | |
| IL212596A (en) | Octenidine or pharmaceutical salt thereof for combined therapeuitc administration in solution with a polyalcohol | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| MX352281B (en) | Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy. | |
| MX2009006325A (en) | 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents. | |
| MX2013002208A (en) | Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes. | |
| RU2015112121A (en) | MI-RNA AND THEIR APPLICATION IN METHODS AND COMPOSITIONS FOR TREATMENT AND / OR PREVENTION OF EYE CONDITIONS | |
| UA93365C2 (en) | Injectable preparations of diclofenic and its pharmaceutically acceptable salts, and processes for the preparation thereof | |
| BR112012006070A2 (en) | compositions and methods for treating seizure disorders. | |
| MX336477B (en) | Amino acid derivative. | |
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| NZ717866A (en) | Compositions and methods for treating bacterial infections using ceftaroline | |
| BRPI0922736A8 (en) | 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracycle citrate salt [19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene | |
| NZ587941A (en) | Methods to inhibit tumor cell growth by using lansoprazole | |
| MX2012005497A (en) | Tivozanib and temsirolimus in combination. | |
| BR112014005653A2 (en) | use of 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazol-2-1l] 1h-quinolin-one to treat cancer in patients with moderate hepatic impairment | |
| RU2010134265A (en) | METHOD FOR TREATING DYSPEPSY IN CALVES | |
| UA116976C2 (en) | A deproteinised calf blood preparation for use in prevention or treatment of post-stroke cognitive impairment | |
| NZ726636A (en) | Novel compounds and compositions for targeting cancer stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: PFIZER ANTI-INFECTIVES AB, SE Effective date: 20170309 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 21 SEP 2020 BY AJ PARK Effective date: 20180226 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2021 BY THOMSON REUTERS Effective date: 20200820 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2022 BY THOMSON REUTERS Effective date: 20210803 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2023 BY THOMSON REUTERS Effective date: 20220801 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 SEP 2024 BY THOMSON REUTERS Effective date: 20230802 |